Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 425

1.

Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-blind Clinical Trial.

Crim C, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Brook RD.

Am J Respir Crit Care Med. 2020 Feb 4. doi: 10.1164/rccm.201908-1639LE. [Epub ahead of print] No abstract available.

PMID:
32017597
2.

Surgical implantation of radio tags in three eel species (Anguilla spp.) in South Africa.

Hanzen C, Lucas MC, O'Brien G, Calverley P, Downs CT.

J Fish Biol. 2020 Jan 31. doi: 10.1111/jfb.14270. [Epub ahead of print]

PMID:
32003468
3.

Home economics for COPD care.

Calverley PMA.

Respirology. 2020 Feb;25(2):124-125. doi: 10.1111/resp.13762. Epub 2019 Dec 16. No abstract available.

4.

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.

Calverley PM, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 2;14:2733-2744. doi: 10.2147/COPD.S221852. eCollection 2019.

5.

Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial.

Wimms AJ, Kelly JL, Turnbull CD, McMillan A, Craig SE, O'Reilly JF, Nickol AH, Hedley EL, Decker MD, Willes LA, Calverley PMA, Benjafield AV, Stradling JR, Morrell MJ; MERGE trial investigators.

Lancet Respir Med. 2019 Dec 2. pii: S2213-2600(19)30402-3. doi: 10.1016/S2213-2600(19)30402-3. [Epub ahead of print]

PMID:
31806413
6.

Technical Standards for Respiratory Oscillometry.

King GG, Bates J, Berger KI, Calverley P, de Melo PL, Dellacà RL, Farré R, Hall GL, Ioan I, Irvin CG, Kaczka DW, Kaminsky DA, Kurosawa H, Lombardi E, Maksym GN, Marchal F, Oppenheimer BW, Simpson SJ, Thamrin C, van den Berge M, Oostveen E.

Eur Respir J. 2019 Nov 26. pii: 1900753. doi: 10.1183/13993003.00753-2019. [Epub ahead of print] No abstract available.

PMID:
31772002
7.

The Pressing Need to Redefine "COPD".

Barnes PJ, Vestbo J, Calverley PM.

Chronic Obstr Pulm Dis. 2019 Nov;6(5):380-383. doi: 10.15326/jcopdf.6.5.2019.0173. No abstract available.

8.

Meeting the GOLD Standard: COPD Treatment in the UK Today.

Calverley PMA.

EClinicalMedicine. 2019 Aug 6;14:3-4. doi: 10.1016/j.eclinm.2019.07.016. eCollection 2019 Sep. No abstract available.

9.

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.

Celli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, Dixon I, Kim V, Martinez FJ, Morris A, Newby DE, Yates J, Vestbo J.

BMJ Open Respir Res. 2019 May 4;6(1):e000431. doi: 10.1136/bmjresp-2019-000431. eCollection 2019.

10.

Detection of Expiratory Flow Limitation by Forced Oscillations during Noninvasive Ventilation.

Zannin E, Chakrabarti B, Govoni L, Pompilio PP, Romano R, Calverley PMA, Dellacà RL.

Am J Respir Crit Care Med. 2019 Oct 15;200(8):1063-1065. doi: 10.1164/rccm.201903-0570LE. No abstract available.

PMID:
31241980
11.

Genetics, Chronic Obstructive Pulmonary Disease, and the Arrow of Time.

Calverley PMA, Walker PP.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):654-655. doi: 10.1164/rccm.201904-0813ED. No abstract available.

12.

Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT.

Celli BR, Anderson JA, Brook RD, Calverley PMA, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Vestbo J.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900278. doi: 10.1183/13993003.00278-2019. Print 2019 Jun. No abstract available.

PMID:
30923182
13.

Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey.

Jenkins C, FitzGerald JM, Martinez FJ, Postma DS, Rennard S, van der Molen T, Gardev A, Genofre E, Calverley P.

Clin Respir J. 2019 Jun;13(6):355-367. doi: 10.1111/crj.13016. Epub 2019 Mar 24.

PMID:
30825365
14.

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.

Vestbo J, Dransfield M, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Lange P.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00203-2018. doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.

15.

Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.

Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA.

Respir Med. 2019 Feb;147:37-43. doi: 10.1016/j.rmed.2018.12.014. Epub 2019 Jan 9.

PMID:
30704697
16.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

17.

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

Ferguson GT, Buhl R, Bothner U, Hoz A, Voß F, Anzueto A, Calverley PMA.

Respir Med. 2018 Oct;143:67-73. doi: 10.1016/j.rmed.2018.08.012. Epub 2018 Aug 28.

18.

Patient-centered Outcomes Research in Pulmonary, Critical Care, and Sleep Medicine. An Official American Thoracic Society Workshop Report.

Feemster LC, Saft HL, Bartlett SJ, Parthasarathy S, Barnes T, Calverley P, Curtis JR, Hickam DH, Mularski RA, Au DH, Chlan LL, Reinke LF, Cooke CR, Cox CE, Krishnan JA, Rubin E, Shah S, Sullivan DR, Kross EK; American Thoracic Society Behavioral Sciences and Health Services Research Assembly and Nursing Assembly.

Ann Am Thorac Soc. 2018 Sep;15(9):1005-1015. doi: 10.1513/AnnalsATS.201806-406WS.

19.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL.

J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137. doi: 10.1016/j.jacc.2018.06.051. Erratum in: J Am Coll Cardiol. 2018 Oct 30;72(18):2282.

20.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD; SUMMIT Investigators.

Eur Heart J. 2018 Sep 1;39(33):3128-3134. doi: 10.1093/eurheartj/ehy451.

PMID:
30101300
21.

Whole exome sequencing analysis in severe chronic obstructive pulmonary disease.

Qiao D, Ameli A, Prokopenko D, Chen H, Kho AT, Parker MM, Morrow J, Hobbs BD, Liu Y, Beaty TH, Crapo JD, Barnes KC, Nickerson DA, Bamshad M, Hersh CP, Lomas DA, Agusti A, Make BJ, Calverley PMA, Donner CF, Wouters EF, Vestbo J, Paré PD, Levy RD, Rennard SI, Tal-Singer R, Spitz MR, Sharma A, Ruczinski I, Lange C, Silverman EK, Cho MH.

Hum Mol Genet. 2018 Nov 1;27(21):3801-3812. doi: 10.1093/hmg/ddy269.

22.

Lung Function through the PRISm. Spreading Light or Creating Confusion?

Lundbäck B, Backman H, Calverley PMA.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1358-1360. doi: 10.1164/rccm.201806-1163ED. No abstract available.

PMID:
30016598
23.

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.

Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC.

PMID:
29763572
24.

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.

Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 23;13:1297-1308. doi: 10.2147/COPD.S153631. eCollection 2018.

25.

Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study.

Mohan D, Forman JR, Allinder M, McEniery CM, Bolton CE, Cockcroft JR, MacNee W, Fuld J, Marchong M, Gale NS, Fisk M, Nagarajan S, Cheriyan J, Lomas DA, Calverley PMA, Miller BE, Tal-Singer R, Wilkinson IB, Polkey MI; ERICA Consortium.

Thorax. 2018 Dec;73(12):1182-1185. doi: 10.1136/thoraxjnl-2018-211556. Epub 2018 Apr 4.

PMID:
29618495
26.

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.

Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, Wedzicha J, Rabe KF.

Lancet Respir Med. 2018 May;6(5):337-344. doi: 10.1016/S2213-2600(18)30102-4. Epub 2018 Apr 5.

PMID:
29605624
27.

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.

Watz H, Bagul N, Rabe KF, Rennard S, Alagappan VK, Román J, Facius A, Calverley PM.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 6;13:813-822. doi: 10.2147/COPD.S154012. eCollection 2018.

28.

Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial.

Walker PP, Pompilio PP, Zanaboni P, Bergmo TS, Prikk K, Malinovschi A, Montserrat JM, Middlemass J, Šonc S, Munaro G, Marušič D, Sepper R, Rosso R, Siriwardena AN, Janson C, Farré R, Calverley PMA, Dellaca' RL.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):620-628. doi: 10.1164/rccm.201712-2404OC.

PMID:
29557669
29.

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial.

Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.

30.

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57. doi: 10.1164/rccm.201711-2239OC.

31.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

Celli B, Anderson JA, Brook R, Calverley P, Crim C, Holmes AP, Martinez FJ, Newby DE, Yates J, Vestbo J; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1641-1644. doi: 10.1164/rccm.201710-2052LE. No abstract available.

PMID:
29412688
32.

At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available. Erratum in: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463.

33.

β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.

Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates J, Vestbo J, Newby DE; SUMMIT Investigators.

Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.

PMID:
29406772
34.

Cigarette smoking and response to inhaled corticosteroids in COPD.

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Newby DE, Vestbo J, Yates JC, Dransfield MT.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701393. doi: 10.1183/13993003.01393-2017. Print 2018 Jan. No abstract available.

35.

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.

Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M.

Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10.

PMID:
29331313
36.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

37.

Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis.

Anzueto A, Calverley PMA, Mueller A, Metzdorf N, Haensel M, Jardim JR, Pizzichini E, Giraldo H, Ramirez-Venegas A, Giugno ER.

Arch Bronconeumol. 2018 Mar;54(3):140-148. doi: 10.1016/j.arbres.2017.11.010. Epub 2018 Jan 6. English, Spanish.

38.

Reply: Chronic Obstructive Pulmonary Disease: Defining the Indefinable.

Calverley P.

Ann Am Thorac Soc. 2018 Mar;15(3):390-391. doi: 10.1513/AnnalsATS.201711-902LE. No abstract available.

PMID:
29262263
39.

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.

Calverley PM, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 29;12:3391-3405. doi: 10.2147/COPD.S145814. eCollection 2017.

40.

Triple Therapy in COPD: What We Know and What We Don't.

Calverley PMA, Magnussen H, Miravitlles M, Wedzicha JA.

COPD. 2017 Dec;14(6):648-662. doi: 10.1080/15412555.2017.1389875. Epub 2017 Nov 9. Review.

PMID:
29120273
41.

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.

Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA; RESTORE group; RESTORE study.

Eur Respir J. 2017 Oct 12;50(4). pii: 1700711. doi: 10.1183/13993003.00711-2017. Print 2017 Oct.

42.

The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants.

Calverley PMA, Mueller A, Fowler A, Metzdorf N, Wise RA.

Ann Am Thorac Soc. 2018 Feb;15(2):200-208. doi: 10.1513/AnnalsATS.201703-194OC.

PMID:
28957643
43.

Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic.

Calverley PMA.

Eur Respir J. 2017 Sep 27;50(3). pii: 1701376. doi: 10.1183/13993003.01376-2017. Print 2017 Sep. No abstract available.

44.

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J; SUMMIT investigators.

Respir Med. 2017 Oct;131:27-34. doi: 10.1016/j.rmed.2017.07.060. Epub 2017 Aug 1.

PMID:
28947039
45.

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, Miravitlles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602265. doi: 10.1183/13993003.02265-2016. Print 2017 Sep.

46.

The association of tidal EFL with exercise performance, exacerbations, and death in COPD.

Aarli BB, Calverley PM, Jensen RL, Dellacà R, Eagan TM, Bakke PS, Hardie JA.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 26;12:2179-2188. doi: 10.2147/COPD.S138720. eCollection 2017.

47.

A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.

Calverley PMA, Sethi S, Dawson M, Ward CK, Finch DK, Penney M, Newbold P, van der Merwe R.

Respir Res. 2017 Aug 9;18(1):153. doi: 10.1186/s12931-017-0633-7.

48.

Physical activity patterns and clusters in 1001 patients with COPD.

Mesquita R, Spina G, Pitta F, Donaire-Gonzalez D, Deering BM, Patel MS, Mitchell KE, Alison J, van Gestel AJ, Zogg S, Gagnon P, Abascal-Bolado B, Vagaggini B, Garcia-Aymerich J, Jenkins SC, Romme EA, Kon SS, Albert PS, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Benzo RP, Maltais F, Paggiaro P, McKeough ZJ, Polkey MI, Hill K, Man WD, Clarenbach CF, Hernandes NA, Savi D, Wootton S, Furlanetto KC, Cindy Ng LW, Vaes AW, Jenkins C, Eastwood PR, Jarreta D, Kirsten A, Brooks D, Hillman DR, Sant'Anna T, Meijer K, Dürr S, Rutten EP, Kohler M, Probst VS, Tal-Singer R, Gil EG, den Brinker AC, Leuppi JD, Calverley PM, Smeenk FW, Costello RW, Gramm M, Goldstein R, Groenen MT, Magnussen H, Wouters EF, ZuWallack RL, Amft O, Watz H, Spruit MA.

Chron Respir Dis. 2017 Aug;14(3):256-269. doi: 10.1177/1479972316687207. Epub 2017 Feb 24.

49.

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.

Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR; SUMMIT (Study to Understand Mortality and Morbidity) Investigators.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55. doi: 10.1164/rccm.201610-2086OC.

PMID:
28737971
50.

Where to start when treating COPD?

Calverley PMA.

Respirology. 2017 Oct;22(7):1239-1240. doi: 10.1111/resp.13126. Epub 2017 Jul 16. No abstract available.

Supplemental Content

Loading ...
Support Center